

**Personalised Approaches to Reduce Adverse Drug Reactions from Polypharmacy****Partnership Search****€ 38 M**

Total budget

**€ 8–10 M**

EU grant per project

**29 Oct 2026**

Call opens

**17 Feb 2027**

Submission deadline

**Why This Matters**

Adverse Drug Reactions (ADRs) from polypharmacy – taking 3 or more drugs simultaneously – are among the most preventable causes of patient harm in Europe.

**5%** of all in-hospital deaths are caused by ADRs.

**16%** of hospitalised older patients experience significant ADRs – most preventable.

**Call at a Glance**

**Type:** Research & Innovation Action (RIA)

**Stage:** Single stage

**Thresholds:** Excellence / Impact / Implementation ≥ 4 each (total ≥ 12)

**Eligibility:** EU + Associated Countries; US entities eligible (NIH reciprocity)

**Thematic Scope****Pharmacogenomics**

- ▶ PK/PD & pharmacogenomics for ADR prediction
- ▶ Biomarker identification & patient stratification
- ▶ Drug–drug / drug–gene / drug–food interactions
- ▶ In-vitro & in-silico ADR models
- ▶ Sex differences in drug response

**Digital Health & AI**

- ▶ EHR integration for medication safety
- ▶ AI-driven ADR pattern recognition
- ▶ Clinical decision support with genomic data
- ▶ Cost-effectiveness of pharmacogenomics-guided care
- ▶ Regulatory science for clinical translation

**Policy & Implementation**

- ▶ Ethical & regulatory challenges
- ▶ Deprescribing & guideline revision
- ▶ Data sharing with EMA
- ▶ Education for clinicians & patients
- ▶ Alignment with EU Partnerships

**Consortium – Partner Profiles Sought****Research & Academia**

- ▶ Clinical pharmacology & genomics
- ▶ Health informatics & bioinformatics
- ▶ Health technology assessment
- ▶ Biostatistics & clinical trials

**Clinical & Healthcare**

- ▶ University hospitals & clinical centres
- ▶ Primary care & geriatric medicine
- ▶ Clinical pharmacy departments
- ▶ Patient registries & biobanks

**Industry & Policy**

- ▶ Health IT, AI & EHR platforms
- ▶ Biotech & diagnostics SMEs
- ▶ Regulatory affairs specialists
- ▶ Health payers & policy bodies

**Already on Board****ESSENCE LINE, s.r.o. (CZ)****SME · Biotechnology & Pharmacogenetics**

Specialised in pharmacogenetic testing and analysis – bridging genomic data with personalised drug therapy decisions.

**Fraunhofer ENAS (DE)****Research Institute · Smart Microsystems & Medical Technology**

Develops miniaturised lab-on-chip systems, smart biosensors and AI-driven data analysis for medical applications.

**NUDZ – National Institute of Mental Health (CZ)****Clinical Research Centre**

Access to schizophrenia and Alzheimer's patient cohorts, with deep expertise in psychiatric pharmacology and clinical trials.

**Interested? Let's Talk.**

We are actively building the consortium and aim to have partners confirmed by Q3 of 2026.

✉ [vojtechvinduska@essenceline.cz](mailto:vojtechvinduska@essenceline.cz)

🌐 [www.essenceline.cz](http://www.essenceline.cz)

☎ (+420) 273 130 999

